NCT01209741View on ClinicalTrials.gov

Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Migraine
Interventions
DRUG

telcagepant potassium

\[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods

DRUG

MK-0974 5Mo5C

Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 °C) 300 mg in one of three treatment periods

DRUG

MK-0974 12Mo5C

Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 °C) 300 mg in one of three treatment periods

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01209741 - Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED) | Biotech Hunter | Biotech Hunter